A neoteric annotation on the advances in combination therapy for Parkinson’s disease: nanocarrier-based combination approach and future anticipation. Part I: exploring theoretical insights and pharmacological advances,Expert Opinion on Drug Delivery

当前位置： X-MOL 学术 › Expert Opin. Drug Deliv. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A neoteric annotation on the advances in combination therapy for Parkinson’s disease: nanocarrier-based combination approach and future anticipation. Part I: exploring theoretical insights and pharmacological advances
Expert Opinion on Drug Delivery ( IF 6.6 ) Pub Date : 2024-03-14 , DOI: 10.1080/17425247.2024.2331214
Devika Unnithan ₁ , Ali Sartaj ₁ , Mohammad Kashif Iqubal ₂ , Javed Ali ₁ , Sanjula Baboota ₁

Affiliation

Parkinson’s disease is a neurological condition defined by a substantial reduction in dopamine-containing cells in the substantia nigra. Levodopa (L-Dopa) is considered the gold standard in treatme...

中文翻译：